Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development

2026-03-20 13:55:32 ET

The last time I spoke about Assembly Biosciences ( ASMB ) it was in a Seeking Alpha article entitled " Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts ." With respect to this article, I mentioned that the company was working on the development of two long-acting helicase-primase inhibitors [HPIs], ABI-5366 and ABI-1179, for the treatment of patients with recurrent genital herpes with Gilead Sciences ( GILD ). The company reported positive data throughout 2025 with respect to the HPI program, which was a huge win for the expected catalysts that took place....

Read the full article on Seeking Alpha

For further details see: